Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000934
Chunk: 44

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 44
---
 Agreement and
ending on the date of that is one Business Day following the termination of this Agreement as provided in Section 11, the Investor and
its agents, representatives and affiliates, including any entity managed or controlled by the Investor shall not, directly or indirectly,
in any manner whatsoever (i) enter into or effect, directly or indirectly, any (x) “short sale” (as such term is defined in
Rule 200 of Regulation SHO of the Exchange Act) of the Depositary Shares or (y) hedging transaction, which establishes a net short position
with respect to the Depositary Shares or (ii) be in violation of Regulation SHO. In addition to the foregoing, in connection with any
sale of Securities, the Investor shall comply in all respects with all applicable laws, rules, regulations and orders, including, without
limitation, the requirements of the Securities Act and the Exchange Act.

(e) . In consideration for the Investor’s execution and delivery of this Agreement, the Investor shall be entitled to receive
a fee of $875,000 (equaling 2.5% of the Available Amount) in cash in immediately available funds to an account designated by the Investor,
which amount shall be due and payable on the Execution Date, as a commitment fee (the “”), of which (i)
1.75% of the Available Amount ($612,500) shall be paid to the Investor on the Execution Date (the “”)
and (ii) the balance of such Commitment Fee shall by paid to the Investor, in a pro rata fashion, simultaneously with the delivery of
any and all Purchase Shares purchased under this Agreement under every Fixed Purchase Notice, VWAP Purchase Notice and/or Additional VWAP
Purchase Notice (each a “”). In the event that the Company fails to pay the applicable portion
of the Commitment Fee to the Investor on the relevant Commitment Fee Payment Date, the Company shall have the right, at the Company’s
discretion, to issue Depositary Shares representing the value of the applicable portion of the Commitment Fee in the aggregate (valued
at the closing sale price for the Depositary Shares on the Primary Market on the Business Day immediately prior to the Execution Date)
(collectively, the “”) to release the Company of its liability to pay such portion of the Commitment
Fee to the Investor as a liquidated sum, which shall be issued by the Company to the Investor within five (5) Business Days after the
relevant Commitment Fee